🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this Expanded Access Program (EAP) is to enable the use of 8...
Status
No Longer Available
Location
Arkansas Urology
Start Date
TBD
Trial ID
NCT06090331
Treatments Being Tested
A prospective, open-label, phase 2 study to explore CAIX expression through...
Status
Terminated
Location
University of California, Los Angeles(UCLA)
Start Date
2023-06-06
Trial ID
NCT05563272
Treatments Being Tested
The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET s...
Status
Not Yet Recruiting
Location
Massachusetts General Hospital
Start Date
2026-09-16
Trial ID
NCT07077083
Treatments Being Tested
89Zr-TLX250 is a carbonic anydrase IX (CAIX)-targeted imaging agent that is...
Status
Completed
Location
Yokohama City University Hospital
Start Date
2020-08-01
Trial ID
NCT04496089
Treatments Being Tested
89Zr-TLX250 is under clinical development as a diagnostic agent targeting c...
Status
Recruiting
Location
Beijing Cancer Hospital
Start Date
2024-11-06
Trial ID
NCT06750419
Treatments Being Tested
The study is designed to explore the safety and tolerability as well as dia...
Status
Completed
Location
Radboud University
Start Date
2018-04-05
Trial ID
NCT03556046
Treatments Being Tested
The purpose of this study is to evaluate the use of 89Zr-labeled girentuxim...
Status
Completed
Location
ICO René Gauducheau
Start Date
2021-09-21
Trial ID
NCT04758780
Treatments Being Tested
The purpose of this study is to evaluate the use of 89Zr-labeled girentuxim...
Status
Completed
Location
Institut de cancerologie de l'Ouest
Start Date
2021-12-15
Trial ID
NCT04897763
Treatments Being Tested
89Zr-TLX250 is under clinical development as a diagnostic agent targeting c...
Status
Completed
Location
City of Hope Comprehensive Cancer Center
Start Date
2019-08-15
Trial ID
NCT03849118
Treatments Being Tested
The study is designed to evaluate the safety, tolerability, radiation dosim...
Status
Completed
Location
Peking University Cancer Hospital & Institute
Start Date
2023-06-26
Trial ID
NCT05861778
Treatments Being Tested